Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00039507

Enrollment

Unknown

Registered

2003-01-27

Start date

2002-06-30

Completion date

2004-02-29

Last updated

2010-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

stage I non-small cell lung cancer, stage II non-small cell lung cancer

Brief summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

Detailed description

OBJECTIVES: * Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer. * Determine the treatment-related toxicity in patients treated with this therapy. * Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients. OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection. PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Interventions

PROCEDUREconventional surgery

PROCEDUREradiofrequency ablation

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of malignant non-small cell lung cancer (NSCLC) * Intraoperative needle biopsy confirmation allowed * Resectable disease (stage I or II) * All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection * Medically fit to undergo lung resection PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior or concurrent biologic therapy Chemotherapy: * No prior or concurrent chemotherapy Endocrine therapy: * No prior or concurrent endocrine therapy Radiotherapy: * No prior or concurrent radiotherapy Surgery: * See Disease Characteristics Other: * No other prior therapy for NSCLC

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026